Bexotegrast is a small molecule commercialized by Pliant Therapeutics, with a leading Phase III program in Idiopathic Pulmonary Fibrosis. According to Globaldata, it is involved in 11 clinical trials, of which 7 were completed, 3 are ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Bexotegrast’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Bexotegrast is expected to reach an annual total of $464 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Bexotegrast Overview
Bexotegrast (PLN-74809) is under development for the treatment of primary sclerosing cholangitis, idiopathic pulmonary fibrosis (IPF), liver fibrosis and COVID-19-related acute respiratory distress syndrome. The drug candidate acts by targeting integrin alpha 5 beta 6 and integrin alpha 5 beta 1.
Pliant Therapeutics Overview
Pliant Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops novel therapies for the treatment of fibrosis. The company’s pipeline products include PLN-74809, PLN-101095, PLN-101325 and PLN-1474. Its pipeline candidates treat idiopathic pulmonary fibrosis (IPF), primary sclerosing cholangitis (PSC), solid tumors, other muscular dystrophies and NASH-associated liver fibrosis. The company is also evaluating therapies to treat muscular dystrophy, solid tumors, and cancer. It works in partnership with Novartis AG and other institutions, universities, medical centers, physicians and researchers to develop its products. Pliant Therapeutics is headquartered in South San Francisco, California, the US.
The company reported revenues of (US Dollars) US$9.7 million for the fiscal year ended December 2022 (FY2022), an increase of 27.9% over FY2021. The operating loss of the company was US$127.2 million in FY2022, compared to an operating loss of US$97.5 million in FY2021. The net loss of the company was US$123.3 million in FY2022, compared to a net loss of US$97.3 million in FY2021.
For a complete picture of Bexotegrast’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.